Ian Lipkin: Diagnostics, therapeutics and social engagement at MSPH
Dr. Lipkin is looking for testing assays that are more efficient to provide increased diagnostic capability and capacity. Some of these include developing more sensitive triplex assays that can also detect the flu. His laboratory is supporting four collaborative projects for Phase II clinical trials: Randomized Phase II Open label trial of severely ill patients (PI: Max O’Donnell) Phase II trial on healthcare workers Randomized Double-Blinded Phase II trial of subjects who have been in close contact with patients who are positive but are unaffected (no or mild symptoms) (PI: Jessica Justman) Randomized double-blinded Phase II trial of CP in hospital workers (needs a new PI but currently Elizabeth Oelsner) Also, MSPH is focusing on creating public service announcements
